Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
5% Minoxidil Foam · 1 trial · 1 indication
Number of hairs in the area being examined as measured by macrophotography.
Subject assessment of scalp coverage at Week 24 was measured as change from Baseline on a 7-point scale where 0 meant no perceived change in scalp coverage, +1 to +3 indicated progressively increased levels of scalp coverage, and -1 to -3 indicated progressively decreased levels.
| Arm | Type | Description |
|---|---|---|
| Minoxidil Foam | EXPERIMENTAL | 5% Minoxidil Topical Foam |
| Vehicle Foam | PLACEBO_COMPARATOR | Vehicle Topical Foam |
| Name | Type | Description |
|---|---|---|
| 5% Minoxidil Topical Foam | DRUG | Dosage Form: 5% Minoxidil Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks |
| Vehicle Topical Foam | DRUG | Dosage Form: Vehicle Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks |
Inclusion Criteria: * females, age 18 or older in general good health * exhibits female pattern hair loss * signs and dates an informed consent document * agrees to use an adequate method of birth control; if of childbearing potential * shows a negative urine pregnancy test at Screening Visit * is ...
5% Minoxidil Foam is used for androgenetic alopecia, a common form of hair loss. It is a topical foam formulation of minoxidil, a small molecule, applied to the scalp to promote hair regrowth. The drug is being developed by Johnson & Johnson for this dermatological condition.
Johnson & Johnson (NYSE: JNJ) is the developer of 5% Minoxidil Foam. The company is conducting clinical research on this topical foam for the treatment of androgenetic alopecia, also known as pattern hair loss.
5% Minoxidil Foam is in Phase 3 clinical development. It has completed one Phase 3 trial, which was a randomized, double-blind, placebo-controlled study. The drug is investigational and has not been approved by regulatory authorities based on the available data.
5% Minoxidil Foam has one completed Phase 3 trial, NCT01226459, titled 'Clinical Trial in Females for Female Pattern Hair Loss.' The study enrolled 404 female participants with androgenetic alopecia across the United States, France, Germany, and the United Kingdom.
5% Minoxidil Foam is a specific formulation of minoxidil, a small molecule used to treat hair loss. The foam is designed for topical application to the scalp. It is being studied for androgenetic alopecia, and the completed trial focused on female pattern hair loss.